Low 5-year survival rates, increasing incidence, as well as the specific challenges of targeting pancreatic cancer, clearly support an urgent need for new multifunctional drugs for the prevention and treatment of this fatal disease. Natural products, such as abietane-type diterpenoids, are widely studied as promiscuous anticancer agents. In this study, dehydroabietic oximes were identified as potential compounds to target pancreatic cancer and cancer-related inflammation. The compounds inhibited the growth of human pancreatic cancer Aspc-1 cells with IC 50 values in the low micromolar range and showed anti-inflammatory activity, measured as the inhibition of nitric oxide production, an important inflammatory mediator in the tumour microenvironment. Further studies revealed that the compounds were able to induce cancer cell differentiation and concomitantly downregulate cyclin D1 expression with upregulation of p27 levels, consistent with cell cycle arrest at the G1 phase. Moreover, a kinase profiling study showed that one of the compounds has isoform-selective, however modest, inhibitory activity on RSK2, an AGC kinase that has been implicated in cellular invasion and metastasis.
Pancreatic cancer is the fourth leading cause of death by cancer in Europe and in the US 1 . In the US alone, it is estimated that over 55 000 new cases of pancreatic cancer will be diagnosed in 2018. The increasing incidence and death rates alarmingly suggest that it will become the second leading cause of cancer-related deaths before 2030 2, 3 . The current treatment protocols for patients with pancreatic cancer include surgery, with partial or total removal of the pancreas, radiation therapy, and mixed-drug chemotherapy, depending on the type and stage of the diagnosed cancer. Nonetheless, the 5-year survival rates for this fatal disease still remain at 9% in the US and 3% in Europe, with most patients succumbing to the disease between 4.6 months and 2 years after diagnosis, clearly demonstrating the need to improve early diagnosis and to provide more effective and safer treatments. Pancreatic cancer is particularly hard to target because 67-100% of tumours contain on average 63 genetic mutations per cancer, involving the impressive number of 12 altered cellular signalling pathways and processes 4 . Therefore, developing multifunctional compounds able to reach several relevant drug targets, that modulate entire regulatory networks or multiple pathways, being both preventive and therapeutic, is much more likely to serve as an effective treatment for this devastating disease 5, 6 .
Nature is an important source for finding new anticancer drugs. Between 1981 and 2014, 83% of all approved small molecule anticancer drugs were either natural products or their derivatives or natural product mimicks 7 . Terpenoids are a large group of phytochemicals that have been explored as potential cytoprotective and chemopreventive agents. According to several preclinical animal model studies, both naturally occurring and semi-synthetic terpenoids act at various stages of tumour development including inhibiting initiation and promotion of carcinogenesis, inducing tumour cell differentiation and apoptosis, and suppressing tumour angiogenesis [8] [9] [10] [11] [12] [13] . For instance, two derivatives of the triterpenoid oleanolic acid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester (bardoxolone methyl or CDDO-Me), progressed SCienTiFiC RepoRts | (2018) 8:15923 | DOI:10.1038/s41598-018-34131-1 into phase I clinical trials for the treatment of leukaemia as well as solid tumours and lymphoid malignancies 6, 14, 15 .
Highly oxygenated abietane-type diterpenoids such as triptolide and minnelide, and tanshinone A, have been studied for the treatment of pancreatic cancer [16] [17] [18] [19] [20] . Minnelide is a prodrug of triptolide with improved solubility and is currently being tested in clinical trials for advanced tumours including pancreatic cancer 21, 22 . Dehydroabietic acid (1, Fig. 1) is an aromatic abietane-type diterpenoid which has been reported to possess anticancer activities against several cancer types, and using it as a starting material in an attempt to improve its bioactive properties, a number of semi-synthetic derivatives have been produced 19, 20 . However, to the best of our knowledge, very little is known about the potential effects of 1 and its derivatives against pancreatic cancer. More importantly, 1 is an agonist of the peroxisome proliferator-activated receptor γ (PPAR-γ) and suppresses the production of pro-inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1/CCL2), tumour necrosis factor α (TNF-α) and nitric oxide (NO), making it potentially relevant for the treatment of cancer-related inflammation 23, 24 . Thus, 1 is a highly promising molecular scaffold for the development of innovative multifunctional drugs for the treatment and prevention of cancer. Herein we report the design, synthesis and evaluation of 1 and a panel of its semisynthetic derivatives against pancreatic cancer cells. We tested the ability of the compounds to block inflammation and induce cancer differentiation and carried out target deconvolution studies to propose a possible mode of action for the most promising compounds in the study.
Results and Discussion
Oxidised derivatives of 1 inhibit the proliferation of pancreatic cancer cells and supress NO formation. We first tested our in-house library of oxidised derivatives of 1 (Fig. 1 ) 25 for their potential to inhibit the proliferation of human Aspc-1 and mouse PanAsc 2159 pancreatic cancer cell lines using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay ( Table 1) . As the inflammatory process within the tumour microenvironment has been demonstrated to have a major role in the pathogenesis and progression of cancer 26 , we also tested the ability of the compounds to block the formation of NO, an important mediator of inflammation, using mouse macrophage-like cells (RAW 264.7) treated with various concentrations of the compounds and stimulated with interferon-γ (INFγ). The starting material 1 was inactive against all the tested cell lines, even when tested at the high concentration of 60 μM. Among the oxidised products we found that only 3 and 6, two ester derivatives bearing a carbonyl group at position 7 were active against the tested cell lines, yet none of the prepared compounds inhibited the production of pro-inflammatory NO, representing still a modest improvement in activity compared to the parent compound.
7-Pyridyl derivatives of 1 have improved anti-proliferative and anti-inflammatory profiles against pancreatic cancer cells.
A recent analysis revealed that 59% of all small-molecule drugs contain a nitrogen heterocycle, clearly demonstrating their relevance as privileged moieties among pharmaceuticals 27 . In this analysis, the top three spots were ruled by pyridine, piperidine, and piperazine. Indeed, pyridyl groups tend to increase metabolic stability 28 and have been used to improve the drug-like properties of natural products 29 . Moreover, pyridyl group additions to several terpenoids have resulted in an improvement of their anticancer properties 28 . Therefore, we hypothesized that coupling of a nitrogen heterocycle to 1 could result in a set of compounds with improved bioactivity. Insertion of a pyridyl group at C7 of compounds 3, 6 and 10 was accomplished by Suzuki cross-coupling ( Fig. 2 ) via the preparation of the corresponding vinyl triflate intermediates 11, 16 and 19 30 . The and Aspc-1 cells were treated for 48 hours with the compounds and the protein expression of p27 and cyclin D1 was investigated. p27 is a cyclin-dependent kinase inhibitor that regulates the activity of cyclin-dependent kinases (CDKs). Low levels of p27 are generally associated with several cancers, including that of the pancreas 34 . The amount of cyclin D1 is important for the cells to progress from the G1 phase forward into S phase and start copying their DNA. If the balance of stimulatory versus inhibitory signals is towards cell growth and division the amount of cyclin D1 increases which leads to its binding to CDK4 and CDK6. Overexpression of cyclin D1 is common in pancreatic cancer 35, 36 .
The western blot analysis on PanAsc 2159 cells ( Fig. 4B ) revealed a dose-dependent down-regulation of cyclin D1 for and induction of p27 after treatment with 23, 26, 29 however not with 24 and 25. Compound 1 did not affect any of the measured markers even at the high concentration of 20 μM. Aspc-1 cells ( Fig. 4A ) did not express cyclin D1 but p27 was up-regulated in a dose-dependent manner for all tested compounds apart from 1 where the effect was the opposite at 20 μM. The cell cycle analysis on Aspc-1 cells showed that with compounds 23-26 and 29, especially at 10 μM concentration, the majority of the cells are in the G1 phase. The histogram (Fig. 4C) shows the results for compound 29 vs. control. In PanAsc 2159 cells ( Fig. 4D ) a similar trend is observed, although not so evident. These findings support the results from the anti-proliferation assays and show that the growth inhibitory properties are likely due to cell cycle arrest in G1 phase, observed in the cell cycle analysis and expressed here as changed levels of cyclin D1 and p27. Of note, for compound 23, only 5 and 10 μM samples were included for the treatment of Aspc-1 cells in western blot analysis because at 20 μM many cells died. At this concentration, cleaved poly (ADP-ribose) polymerase (PARP) was clearly observed, suggesting that cells were dying by apoptosis (data not shown).
Dehydroabietic oximes promote cancer cell differentiation. Regulating cell differentiation is highly
desirable in the context of cancer prevention and treatment 37 . The ability to induce malignant cells to overcome their block of differentiation in order to undergo apoptosis may circumvent the need for a direct cytotoxic effect of drugs and has been correlated with a higher possibility of achieving complete remission and cure. In order to evaluate the ability of the compounds to induce monocyte differentiation, we used human leukaemia cells as a model and CD11b, a cell surface antigen, as a differentiation biomarker. This marker is weakly expressed on leukaemia U937 cells but can be induced with various established differentiation agents such as retinoids or rexinoids. After 4 days of treatment with the compounds, the expression of CD11b was measured by flow cytometry. As shown in Fig. 4 , induction of the expression of CD11b occurred after treatment with all compounds, in a dose-dependent manner, when compared with the control. Compound 29 was the most efficient in inducing CD11b expression, which was particularly evident at 10 μM. Compounds 23 and 25 were also combined with bexarotene, the only FDA-approved rexinoid for the treatment of cutaneous T-cell lymphoma, which has well-established cell differentiation and growth suppression effects 38, 39 , to look for possible synergism. However, no synergistic effects were observed in combination with bexarotene.
Dehydroabietic oximes target the p90 ribosomal S6 kinase 2 (RSK2). The oxime derivatives 23 and 26, differing at the C7 position by the presence of the pyridyl group in 23, were screened against a comprehensive panel of 140 kinases at the International Centre for Kinase Profiling (ICKP), in Dundee, UK (Table S1, Supporting information). Neither compound was found to be a very potent kinase inhibitor as the maximum level of enzyme inhibition was 30-40% at the single concentration tested of 10 μM. However, 26 stood out as being able to inhibit a single kinase by 35%, namely p90 ribosomal S6 kinase 2 (RSK2), an AGC kinase of the RSK family 40, 41 . Notably, concomitant inhibition of RSK1, one of the 4 known isoforms, was not observed. In contrast, the 7-pyridyl containing 23 displayed, in addition to RSK2 inhibition, comparable activity against of a few other kinases especially protein kinase PKBβ (also an AGC kinase), as well as inhibitor of nuclear factor kappa-B kinase β (IKKβ), mammalian sterile 20-like 2 (MST2), proto-oncogene tyrosine kinase protein (Src) and Bruton agammaglobulinemia tyrosine kinase (BTK).
RSKs 1-4 are important downstream mediators of the Ras-ERK signal transduction pathway which, when activated, phosphorylate many substrates, including p27, in both the cytoplasm and nucleus, resulting in cell differentiation, survival, growth and proliferation [40] [41] [42] . RSK2 is abundant in the skeletal muscle, heart and pancreas, and associates with T-cell-restricted intracellular antigen-1 (TIA-1) to localize to stress granules upon oxidative stress. RSK2 can also be activated by phosphorylation on tyrosine residues in response to fibroblast growth factor (FGF) receptor and Src activation. Inhibition of RSKs has been implicated in prevention of cellular invasion and metastasis. Currently there are four classes of RSK inhibitors reported in the literature [41] [42] [43] [44] . However, none is selective towards single enzyme isoforms and addressing isoform selectivity to differentiate between the specific role of each RSK in cancer remains a challenge. In this regard, the selective effect of compound 26 on RSK2 activity seems very promising. In addition, the loss of selectivity in 23 provides important preliminary data to small chemical modifications around the diterpenoid core that can greatly impact this parameter. Thus, dehydroabietic oximes can be regarded as a new chemical class with potential to develop isoform-selective RSK inhibitors. In particular, concomitant inhibition of RSK2 and PKBβ will need to be tackled due to the specific role of the latter in insulin signalling 40 .
Conclusion
Abietane-type diterpenoids such as 1 are excellent scaffolds to develop in search for innovative multifunctional agents for cancer treatment and prevention. In this study, we revealed that dehydroabietic oximes in particular, have multiple desirable actions on cancer cells including anti-proliferative, anti-inflammatory and differentiation-inducing effects. These effects are mediated by depletion of cell cycle proteins such as cyclin D1 and induction of key proteins typically downregulated in many cancers such as p27. Selective inhibition of the AGC kinase RSK2 was also observed, however modest. Nonetheless, this finding paves the way for future investigations of this class of compounds as potential isoform-selective inhibitors of RSKs, which will help to shed light onto their specific roles in cell death and survival. Taken together, our findings suggest that compounds such as dehydroabietic oximes are worth pursuing when searching for novel therapies for cancers such as those of the pancreas, where there is the need to target multiple pathways concomitantly for a better chance of therapeutic success.
Methods
Chemistry. Commercially available reagents and solvents were used without further purification. Reagents were obtained from Pfaltz & Bauer, Sigma Aldrich Co, VWR International Oy or Fluorochem Ltd. All reactions were monitored with thin layer chromatography (TLC) using Silica gel 60 F254 TLC plates. Flash column chromatography (FCC) was made with a Biotage High-Performance Flash Chromatography Sp4-system (Uppsala, Sweden) using a 0.1-mm path length flow cell UV detector/recorder module (fixed wavelength: 254 nm), and 10 g, 25 g or 50 g SNAP cartridges (10-50 mL/min flow rate). Infra-red (IR) spectra were obtained using a Vertex 70 (Bruker Optics Inc., MA, USA) FTIR instrument. The measurements were made with a horizontal attenuated total reflectance (ATR) accessory (MIRacle, Pike Technology, Inc, WI, USA). The transmittance spectra were recorded at a 4 cm −1 resolution between 4000 and 600 cm −1 using the OPUS 5.5 software (Bruker Optics Inc., MA, USA). Nuclear magnetic resonance (NMR) spectra were obtained using a Varian Mercury Plus 300 spectrometer or Bruker Ascend 400 spectrometer, in CDCl 3 , with tetramethylsilane (TMS) as the internal standard. The chemical shifts were reported in parts per million (ppm) and on the δ scale from tetramethylsilane (TMS) as an internal standard. The coupling constants J are quoted in Hertz (Hz). ESI-MS was performed by direct injection or UPLC-MS using a Synapt G2 HDMS (Waters, Milford MA, USA) instrument. Compounds 9-25 and 27-31 are novel. The synthesis of compounds 2-7 was reported previously 23 . Methyl 13-hydroxy-7-oxo-podocarpa-8,11,13-trien-18-oate (9). To a stirred solution of 4 (0.960 g, 2.66 mmol) in dichloromethane (15 mL) was added 4-dimethylaminopyridine (DMAP, 195 mg, 1.60 mmol) and acetic anhydride (1.63 g, 16.0 mmol). The solution was stirred at room temperature for 24 h after which it was diluted with diethyl ether (90 mL) and water was added (30 mL). The aqueous phase was extracted with diethyl ether (2 × 40 mL) and the combined organic phase was washed with water (40 mL) and brine (30 mL) and dried over anhydrous Na 2 SO 4 . After removal of the solvent under reduced pressure a crude compound 8 (1.32 g) was obtained. The crude product was dissolved in acetic acid (10 mL) and the temperature raised to 100 °C. After stirring the solution for 3 h, acetic acid was evaporated and water (30 mL) and diethyl ether (50 mL) were added. The aqueous phase was extracted with diethyl ether (2 × 35 mL) and the combined organic phase was washed with a saturated aqueous solution of NaHCO 3 (25 mL), water (25 mL) and brine (20 mL) and dried over anhydrous Na 2 SO 4 . After removal of the solvent under reduced pressure, the resulting crude product was purified by flash chromatography on silica gel using ethyl acetate in n-hexane (0 to 100%) as the eluent giving compound 9 (510 mg, 63%) as a yellowish solid. 1 The solution was stirred at room temperature for 5 h. The solution was diluted with diethyl ether (20 mL) and a 1 M aqueous solution of HCl (2 mL) was carefully added. The aqueous phase was extracted with diethyl ether (2 × 10 mL) and the combined organic phase was washed with a 1 M aqueous solution of HCl (10 mL), a saturated aqueous solution of NaHCO 3 (10 mL), water (10 mL) and brine (10 mL) and dried over anhydrous Na 2 SO 4 . After removal of the solvent under reduced pressure, the resulting crude product was purified by flash chromatography on silica gel using ethyl acetate in n-hexane (0 to 100%) as the eluent giving compound 10 (57 mg, 88%) as a colourless oil. 1 Methyl 7-pyridyl-abieta-6,8,11,13-tetraen-18-oate (12) . To an argon-flushed flask with 11 (0.208 g, 0.452 mmol) in THF (6 mL) were added bis(triphenylphosphine)palladium(II) dichloride (22.2 mg, 0.0316 mmol) and diethyl(3-pyridyl)borane (99.5 mg, 0.677 mmol). The temperature was raised to 45 °C and a 0.8 M aqueous solution of Na 2 CO 3 (2.2 mL, 3.84 mmol) was added with vigorous stirring. The temperature was further raised to 75 °C and stirring continued for 3.5 h. Solvents were evaporated and the residue was diluted with diethyl ether (30 mL) and a 1 M aqueous solution of HCl was added (5 mL). The aqueous phase was extracted with diethyl ether (2 × 25 mL), and the combined organic phases were washed with a 1 M aqueous solution of HCl (10 mL), water (20 mL) and brine (10 mL), and dried over anhydrous Na 2 SO 4 . After removal of the solvent under reduced pressure, the resulting crude product was purified by flash chromatography on silica gel using ethyl acetate in n-hexane (0 to 80%) as the eluent giving compound 12 (131 mg, 74%) as a white solid. 1 Pyridyl-abieta-6,8,11,13-tetraen-18-ol (13) . To a suspension of lithium aluminium hydride (21.9 mg, 0.578 mmol) in anhydrous THF (2 mL) was added dropwise, at 0 °C, a solution of 12 (0.150 g, 0.385 mmol) in anhydrous THF (2 mL). The suspension was stirred at room temperature for 2.5 h after which the reaction mixture was quenched with methanol (1 mL). Solvents were evaporated and the residue was diluted with diethyl ether (15 mL) and ethyl acetate (5 mL) and water (10 mL). Aqueous phase was extracted with diethyl ether (3 × 15 mL) and the combined organic phases were washed with water (3 × 15 mL) and dried over anhydrous Na 2 SO 4 . After removal of the solvent under reduced pressure, the resulting crude product was purified by flash chromatography on silica gel using ethyl acetate in n-hexane (0-80%) as the eluent to give the product 13 as a white solid (49 mg, 35%). 1 Pyridyl-abieta-6,8,11,13-tetraen-18-oic acid (14) . A mixture of 12 (0.415 g, 1.07 mmol) and potassium hydroxide (0.179 g, 3.20 mmol) in ethylene glycol/water 10:1 (330 μL) was heated to 120 °C. After 4.5 h, diethyl ether (30 mL) and water (20 mL) were added. The aqueous phase was extracted with diethyl ether (3 × 15 mL). Some of the product remained in the aqueous phase so the aqueous phase was acidified with a 1 M aqueous solution of HCl and extracted again with diethyl ether (2 × 15 mL). The combined organic phases were washed with water (50 mL) and brine (40 mL) and dried over anhydrous Na 2 SO 4 . After removal of the solvent under reduced pressure, the resulting crude product was purified by flash chromatography on silica gel using ethyl acetate in n-hexane (0 to 100%) as the eluent to give compound 14 as a white solid (337 mg, 84%). 1 Methyl 12-hydroxyimino-7-pyridyl-abieta-6,8,11,13-tetraen-18-oate (23). Compound 20 (0.300 g, 0.695 mmol) was dissolved in EtOH (3 mL) followed by the addition of hydroxylamine hydrochloride (77.3 mg, 1.11 mmol) and pyridine (85 μL). The solution was stirred at reflux for 2.5 h after which solvents were evaporated and the resulting crude mixture was purified by flash chromatography on silica gel using ethyl acetate in n-hexane (20 to 80%) as the eluent giving compound 23 (150 mg, 48%) as a white solid. 1 
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